Bronchoscopic intervention in the management of primary tracheobronchial adenoid cystic carcinoma with dyspnea.

IF 3.5 3区医学 Q2 ONCOLOGY

Frontiers in Oncology Pub Date : 2025-09-12 eCollection Date: 2025-01-01 DOI:10.3389/fonc.2025.1643239

Xiuxiu Wu, Xiaojian Qiu, Beibei Jin, Jinmu Niu, Yankun Jin, Xiaoning Bu, Juan Wang

{"title":"Bronchoscopic intervention in the management of primary tracheobronchial adenoid cystic carcinoma with dyspnea.","authors":"Xiuxiu Wu, Xiaojian Qiu, Beibei Jin, Jinmu Niu, Yankun Jin, Xiaoning Bu, Juan Wang","doi":"10.3389/fonc.2025.1643239","DOIUrl":null,"url":null,"abstract":"Background: Primary tracheobronchial adenoid cystic carcinoma (TACC) is a rare, slow-progressing malignant tumor whose airway obstruction frequently compromise survival. This study aimed to investigate the value of interventional bronchoscopy in TACC.Methods: We retrospectively analyzed the clinical data of TACC patients treated between January 2006 and December 2024. 52 patients were stratified into two groups: the bronchoscopic intervention alone group (n = 25) and combined therapy group (n = 27). Kaplan-Meier methodology was employed to estimate median progression-free survival (PFS), overall survival (OS), and survival rates. Prognostic factors were further evaluated using Cox proportional hazards model.Results: The mean age of 52 TACC patients was 51.77 ± 14.40 years. Bronchoscopic intervention demonstrated significant reduction in mMRC score and Freitag grade (P < 0.01). Median PFS and OS were 20 months and 118 months, respectively. The 3-/5-/10-year OS were 80.00%, 69.12%, and 34.87%. The combined therapy group exhibited superior PFS compared to the bronchoscopic intervention alone group (P < 0.05). Cox analysis identified combined therapy and stenosis degree as independent prognostic factors for PFS (P < 0.05).Conclusions: Bronchoscopic intervention demonstrated significant efficacy in alleviating dyspnea and airway stenosis while sustaining long-term survival in TACC patients. Multimodal therapy showed potential advantages in delaying disease progression.","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1643239"},"PeriodicalIF":3.5000,"publicationDate":"2025-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12463590/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fonc.2025.1643239","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Primary tracheobronchial adenoid cystic carcinoma (TACC) is a rare, slow-progressing malignant tumor whose airway obstruction frequently compromise survival. This study aimed to investigate the value of interventional bronchoscopy in TACC.

Methods: We retrospectively analyzed the clinical data of TACC patients treated between January 2006 and December 2024. 52 patients were stratified into two groups: the bronchoscopic intervention alone group (n = 25) and combined therapy group (n = 27). Kaplan-Meier methodology was employed to estimate median progression-free survival (PFS), overall survival (OS), and survival rates. Prognostic factors were further evaluated using Cox proportional hazards model.

Results: The mean age of 52 TACC patients was 51.77 ± 14.40 years. Bronchoscopic intervention demonstrated significant reduction in mMRC score and Freitag grade (P < 0.01). Median PFS and OS were 20 months and 118 months, respectively. The 3-/5-/10-year OS were 80.00%, 69.12%, and 34.87%. The combined therapy group exhibited superior PFS compared to the bronchoscopic intervention alone group (P < 0.05). Cox analysis identified combined therapy and stenosis degree as independent prognostic factors for PFS (P < 0.05).

Conclusions: Bronchoscopic intervention demonstrated significant efficacy in alleviating dyspnea and airway stenosis while sustaining long-term survival in TACC patients. Multimodal therapy showed potential advantages in delaying disease progression.

查看原文本刊更多论文

支气管镜介入治疗原发性气管支气管腺样囊性癌伴呼吸困难。

背景：原发性气管支气管腺样囊性癌（TACC）是一种罕见的、进展缓慢的恶性肿瘤，其气道阻塞经常危及生存。本研究旨在探讨介入支气管镜在TACC中的应用价值。方法：回顾性分析2006年1月至2024年12月收治的TACC患者的临床资料。52例患者分为单独支气管镜干预组（n = 25）和联合治疗组（n = 27）。采用Kaplan-Meier方法估计中位无进展生存期（PFS）、总生存期（OS）和生存率。采用Cox比例风险模型进一步评价预后因素。结果：52例TACC患者平均年龄为51.77±14.40岁。支气管镜干预组mMRC评分和Freitag评分均显著降低（P < 0.01）。中位PFS和OS分别为20个月和118个月。3年/5年/10年OS分别为80.00%、69.12%和34.87%。联合治疗组的PFS优于单独支气管镜干预组（P < 0.05）。Cox分析发现联合治疗和狭窄程度是PFS的独立预后因素（P < 0.05）。结论：支气管镜干预在缓解TACC患者呼吸困难和气道狭窄、维持长期生存方面具有显著疗效。多模式治疗在延缓疾病进展方面显示出潜在优势。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Frontiers in Oncology Biochemistry, Genetics and Molecular Biology-Cancer Research

CiteScore

6.20

自引率

10.60%

发文量

6641

审稿时长

14 weeks

期刊介绍： Cancer Imaging and Diagnosis is dedicated to the publication of results from clinical and research studies applied to cancer diagnosis and treatment. The section aims to publish studies from the entire field of cancer imaging: results from routine use of clinical imaging in both radiology and nuclear medicine, results from clinical trials, experimental molecular imaging in humans and small animals, research on new contrast agents in CT, MRI, ultrasound, publication of new technical applications and processing algorithms to improve the standardization of quantitative imaging and image guided interventions for the diagnosis and treatment of cancer.